Apexigen Announces Approximately $2.8 Million Private Placement Financing
SAN CARLOS, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN), a clinical-stage company focused on developing innovative...
Cancer
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance...
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA
Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of...
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology...
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global...
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
Qualigen Therapeutics, Inc. Benedict M. AbuganCARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”...
BriaCell to Investigate Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment...
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial...
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA,...
Cue Biopharma Announces Chief Medical Officer Transition
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a...
IO Biotech Announces Appointment of Devin Smith as General Counsel
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,...
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific...
Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development
Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 MinuteNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) --...
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated...
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy...
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused...
OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the...
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies...